Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PEPTHIV

Financiado

Cerrado

Host defence peptides from neuroendocrine cells as a new source of anti HIV comp...

Host defence peptides from neuroendocrine cells as a new source of anti HIV compounds The AIDS pandemic has been a major challenge to global health for nearly three decades. According to current estimates, over 34 million people are still living with HIV worldwide. Although the introduction of antiretroviral therap... ver más

30/09/2017

UNISTRA

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

UNIVERSITE DE STRASBOURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-09-30 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNISTRA

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

THINPAD Targeting the HIV 1 Nucleocapsid Protein to fight Antiretrov... 7M€ Cerrado

SILENT HIV Paving the way toward HIV eradication control 2M€ Cerrado

ANTIFLU Innovative anti influenza drugs excluding viral escape 8M€ Cerrado

DESARROLLO FARMACÉUTICO Y CLÍNICO DE LA VACUN... DESARROLLO FARMACÉUTICO Y CLÍNICO DE LA VACUNA RUTI PARA REA... 1M€ Cerrado

DESARROLLO CLÍNICO INMUNÓGENO HTI DESARROLLO CLÍNICO INMUNÓGENO HTI 848K€ Cerrado

BIO2010-17039 AGENTES ANTIMALARICOS Y RESPUESTA INMUNE 242K€ Cerrado

Líder del proyecto

UNIVERSITE DE STRASBOURG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The AIDS pandemic has been a major challenge to global health for nearly three decades. According to current estimates, over 34 million people are still living with HIV worldwide. Although the introduction of antiretroviral therapy (HAART) has considerably reduced HIV-related mortality rates, HAART fails to achieve complete viral clearance and still raises drug toxicity and resistance issues. Besides advances in the treatment of HIV infection, numerous efforts have also been made on HIV prevention. However, despite extensive research, no prophylactic HIV vaccine has emerged to date. Consequently, topical microbicides have recently been improved as a solution to moderate HIV transmission but the clinical trials were globally unsatisfactory. As a consequence, innovative approaches to identify new anti-HIV molecules are critical. Host defence peptides (HDPs) constitute an exciting class of drug candidates, especially because they are unlikely to induce drug resistance. HDPs constitute important components of the innate host defence against a broad spectrum of pathogens. To date, several natural biologically active HIV inhibitors have been characterized. However, systematic screens for naturally occurring anti-HIV peptides has been a major failure due to technical issues but also to a limited accessibility of fluids, tissues or organelles enriched in HDPs. Secretory granules are unique organelles in which secretory products are stored upon secretion. Secretory granules of neuroendocrine cells are particularly enriched in HDPs and therefore constitute an excellent model to screen new anti-HIV compounds. Here, we propose an innovative approach to identify new potent anti-HIV peptides, using the secretory granules of neuroendocrine cells as a model. Our long-term goal is to characterize the lead molecules as a prerequisite to the development of new anti-HIV components that can be used as an alternative to HAART or for the development of a new HIV microbicide.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores